Clinical value of liquid biopsy in FGFR2 fusion-positive cholangiocarcinoma patients during targeted therapy.

Alberto Gonzalez-Medina Maria Vila-Casadesús Marina Gómez-Rey Carles Fabregat-Franco Alexandre Sierra Tian V Tian Florian Castet Gloria Castillo Judit Matito Paola Martinez Josep M Miquel Paolo G Nuciforo Raquel Perez-Lopez Teresa Macarulla Ana Vivancos

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

VHIO-iCCA demonstrated accurate detection of FGFR2 fusions in plasma. The integration of information from various plasma biomarkers holds the potential to predict clinical outcomes and identify treatment failure prior to radiological progression, offering valuable guidance for the clinical management of patients with iCCA.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
healthcare
peritoneal dialysis
mass spectrometry
ionic liquid
human health
ultrasound guided
smoking cessation
social media
fine needle aspiration
label free
patient reported